Rheumatoid Arthritis Posts on Medivizor

Posted by Medivizor on Jul 25, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the...

Posted by Medivizor on Jul 21, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study compared the benefit of two doses of filgotinib (Jyseleca) with adalimumab (Humira) and placebo, in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX; Otrexup). The data showed that filgotinib reduced RA signs, improved physical activity, prevented structural joint damage progression, and was...

Posted by Medivizor on Jul 11, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the relationship between tumor necrosis factor-alpha (TNFα), interleukin (IL)-6, and serum certolizumab pegol (CZP; Cimzia) levels in patients with rheumatoid arthritis (RA) treated with CZP. The authors concluded that CZP was highly effective in patients with low serum TNFα levels at 24 hours after...

Posted by Medivizor on Apr 10, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study evaluated whether a modern treatment approach is suitable in patients with rheumatoid arthritis (RA) that were pregnant or intended to become pregnant. The authors concluded that low disease activity (LDA) and remission are possible with a modern approach in these women. Some background RA is an inflammatory disease....

Posted by Medivizor on Feb 13, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study reviewed the effectiveness of baricitinib (Olumiant) on the progression of structural joint damage (SJD) in patients with rheumatoid arthritis (RA). The data showed that baricitinib may significantly help slow down SJD signs found in digital imaging in patients with non-existent or insufficient...